TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of Early Allograft Dysfunction (EAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (complete response and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Ambulatory Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pre-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clinically relevant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall assessment by the patient (Rhinoconjunctivitis Quality of Life Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: progression free survival rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of EBUS-diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopmental outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proper disposal of unused opioids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Food allergy to any intervention allergen
Endpoint domain: Adverse events/effects
Primary endpoint: Ankle dorsiflexion under load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle stability in monopodal loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic postural stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-oriented composite outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vessel-oriented composite outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient symptoms burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time to adequate surgical anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Montgomery and Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of folliculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of obstructive sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Epworth sleepiness scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Epworth sleepiness scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of midostaurin
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of midostaurin
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Post-Resist Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retinal injury morphologies on optical coherence tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal nerve fiber layer thickness on optical coherence tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inner macular layer thickness on optical coherence tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical hypoxic ischemic encephalopathy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI brain injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscular Hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wingate Anaerobic (WnT) Cycle test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Episodic Migraine or Chronic Migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Disability Assessment (MIDAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With TIMI 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: corrected TIMI frame count(frames)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: periodontal pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distal bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with serum testosterone ≤50 ng/dL on Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative percentage of subjects with maintenance of serum testosterone ≤50 ng/dL from Day 29 to Day 85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety of MPT for atrial fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Time between ORI-dropping and dropping of SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline monitor-assessed sedentary time at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline depressive symptoms at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline low back pain symptoms at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in neuropsychological test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Guardian recognition and knowledge of CAMH problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived need for CAMH services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to use accessible CAMH services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Dynamic maximum strength (1-RM) of upper and lower extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of serious device adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Diagnostic Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of diagnosed keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients for Whom Treatment is Feasible
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients That Experience Grade 2 or Greater Lung Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Experience Grade 2 or Greater Esophageal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Optic Nerve Sheath Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean percent change of Non-HDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thoracopulmonary Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Perceived effectiveness of intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glutathione Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life related to tiredness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of participants with GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accumulation of treatment particles in tumor vs normal tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of binge drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Care Recipient Memory and Problem Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in swallowing status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-lead safety ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of infantile colics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Upper extremity functional ability measured with Modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke-related quality of life measured with the Stroke Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Spasticity measured using the Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSHQ Ejaculation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in American Orthopedic Foot and Ankle Society Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Pre-operative Endocrine Prognostic Index (PEPI) score 0 at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Disease specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of AA induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse reaction (AE) and severe adverse reaction (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of lung imaging examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary sodium excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in 17-hydroxyprogesterone (17-OHP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement rate in EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in gastrointestinal symptoms measured with the Gastrointestinal Symptom Rating Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vestibular Time Constant Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Velocity Test Gain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optokinetic After Nystagmus (OKAN) Gain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to elimination of SARS-CoV-2 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to CRP normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to D-dimer normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Target Toenails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Game Score (baseline and performance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' feedback using 5-point Likert scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Therapist subjective evaluation using 5-point Likert scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kappa opioid receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mu opioid receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak PET Mu Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 or higher peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of incomplete abortions
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Clearance of All Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Parasuicidal behaviour
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Site Infection (SSI) at 30-days post-surgery
Endpoint domain: Adverse events/effects
Primary endpoint: treatment emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: changes in viral cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ocular Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in subjective pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained virologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: weight status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retinal Nerve Fiber Layer (RNFL) Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bruch's Membrane Opening-minimum Rim Width (BMO-MRW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in executive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participant-assessed pruritis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital length of hospitalization (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: change in plaque index scores (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in probing Pocket Depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in clinical Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of pro- and anti-thrombotic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Expression of anti-oxidative markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal graft survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Best Spectacle Corrected Visual Acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PASI 75 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of life questionnaire - Core 30 (QLQ-C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of platelet-rich plasma treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety profile of platelet-rich plasma treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Residual Cancer Burden (RCB) 0-I rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in pathogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in ischemic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain-free walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in size of the Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lower Leg Composite of the MRI T2 Relaxation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Quit Hazardous Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and Specificity of Paced Rhythm Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Sum of McGill Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC Breast Cosmetic Rating Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in non-invasive MRI measures of cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neural responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of participants with signs of improvement/worsening of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: number of patients with improved/worsened visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: number of patients with improved/worsened macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: maximally tolerated dose of intracavitary cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Smartcare-NIV system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Achieving Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: colorectal cancer screening initiation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in incisors' positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in position of the root apex of the incisor vertically (UIA-v)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis with SCID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion With STIs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of lexatumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicities (DLTs) of lexatumumab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in post-dose peripheral airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Children's Revised Impact of Event Scale (CRIES-13)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Control of HIV and HCV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cerebral metabolic rate of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Omega-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Methacholine Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage decrease of ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes